Charles M. Baum
2019
Compensation breakdown
| Non-Equity Incentive Plan | $410,506 |
|---|---|
| Option Awards | $7,474,287 |
| Salary | $597,100 |
| Other | $2,500 |
| Total | $8,484,393 |
Baum received $7.5M in option awards, accounting for 88% of the total pay in 2019.
Baum also received $410.5K in non-equity incentive plan, $597.1K in salary and $2.5K in other compensation.
Rankings
In 2019, Charles M. Baum's compensation ranked 991st out of 13,971 executives tracked by ExecPay. In other words, Baum earned more than 92.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 991 out of 13,971 | 93rd |
Division Manufacturing | 338 out of 5,701 | 94th |
Major group Chemicals And Allied Products | 102 out of 2,200 | 95th |
Industry group Drugs | 80 out of 1,886 | 96th |
Industry Pharmaceutical Preparations | 64 out of 1,398 | 95th |
Pay ratio
| Charles M. Baum's Pay | $8,484,393 |
|---|---|
| Median Employee's Pay | $588,168 |
| Pay Ratio | 14to 1 |
In 2019, the annual total compensation of Charles M. Baum was $8,484,393.
The annual total compensation of the median employee at Mirati Therapeutics was $588,168.
The ratio of Charles M. Baum's pay to the pay of median employee was therefore 14 to one.
Baum's colleagues
We found four more compensation records of executives who worked with Charles M. Baum at Mirati Therapeutics in 2019.
2019
James Christensen
Mirati Therapeutics
Chief Scientific Officer
2019
Isan Chen
Mirati Therapeutics
Executive Vice President and Chief Medical and Development Officer
2019
Jamie Donadio
Mirati Therapeutics
Chief Financial Officer
2019
Chris LeMasters
Mirati Therapeutics